Descrizione del progetto
Un sistema di somministrazione di farmaci a base di albumina per l’artrosi
Il trattamento della patologia autoimmune dell’artrosi è principalmente sintomatico e la migliore opzione disponibile prevede la somministrazione intra-articolare (IA) di corticosteroidi liberi e acido ialuronico. Tuttavia, la rapida clearance farmacologica di queste molecole dalle articolazioni richiede più iniezioni e ne rende la somministrazione scomoda e poco efficace. Per affrontare questa limitazione, gli scienziati del progetto IA-NANO, finanziato dall’UE, propongono di sviluppare particelle di albumina caricate con il farmaco antinfiammatorio non steroideo celecoxib. Questo sistema di somministrazione a lunga durata è biocompatibile e biodegradabile, e dovrebbe consentire un rilascio controllato del farmaco nell’articolazione infiammata, riducendo così il numero di iniezioni con farmaco libero e risolvendo la tossicità del sistema.
Obiettivo
Osteoarthritis (OA) is the most common chronic condition of the joints and is predicted to become the fourth largest cause of disability in the world by 2020. Its complete mechanism is yet to be deciphered. Though it is not curable, several medications are prescribed to manage the symptomatic OA, of which the oral and topical medications have shortcomings and the better option is the intra-articular (IA) delivery of free corticosteroids and hyaluronic acid. However, IA delivery is challenging due to the rapid clearance of the free injected molecules from the joint space and outcomes are suboptimal in terms of efficacy and a need for repeated injections. Our objective therefore is to load a candidate drug in a long-acting delivery system and inject it directly into the inflamed knee of a rat model of OA, following in vitro bioassay screening in primary human synoviocytes. Thus, in this project, we propose to develop non-toxic, biocompatible and biodegradable albumin particles loaded with the non-steroidal anti-inflammatory cyclooxygenase-2 inhibitor, celecoxib. This method is expected to reduce the side-effects associated with oral administration of celecoxib. In addition, it will also increase the drug local concentration in the joint and the controlled release of the drug will lead to reduction of inflammatory biomarkers in joints. The project is in line with the EU’s Horizon 2020 Programme focus area - Health, Demographic Change and Wellbeing and UN Sustainable Development goal - Good Health and Well-Being. It will be carried out by the researcher and supervisors who are experts in DDSs development, OA therapy and translational pharmaceutics. Both the researcher and the host are expected to benefit in this collaboration and the researcher will gain experience that will increase her future employability. The project will have great societal impact and commercial potential and will also help increase Europe’s position as the leading source of cutting-edge research.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-IF-EF-ST - Standard EFCoordinatore
4 Dublin
Irlanda